Managed Access Program

Neuraltus is focused on the rigorous clinical development of its investigational therapy, NP001, for the treatment of amyotrophic lateral sclerosis (ALS), and plans to initiate a Phase 2 trial of NP001 in the United States during 2016.  Further details about the Phase 2 trial will be announced at the start of the study and will be made available on the company’s website.
The company has explored several options to simultaneously provide NP001 under a managed or early access program.  Currently, NP001 is not available under any access programs and the therapy has not been reviewed or approved by regulatory authorities.  At this time, Neuraltus does not plan to initiate an access program for NP001.